EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Suzetrigine, a NaV1.8 Inhibitor as a Novel Approach for Pain Therapy—A Medicinal and Chemical Drug Profile

Rawan M Medhat iD, Omnia A Kotb iD, Daniel Baecker iD

Molecules · 20.01.2026 · 31 (2) · 358

DOI: 10.3390/molecules31020358 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 20.01.2026. Verfasst von Rawan M Medhat und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria 21648, Egypt. Hauptthemen laut MEDLINE: Sodium Channel Blockers, NAV1.8 Voltage-Gated Sodium Channel, Analgesics, Pain. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Suzetrigine was approved by the US American Food and Drug Administration in 2025 as the first oral, non-opioid, selective inhibitor of NaV1.8 sodium channel for the treatment of acute pain. Therefore, it represents a groundbreaking advancement in pain management. This review aims to provide an overview of the milestones in the medicinal-chemical development of NaV1.8 inhibitors, eventually leading to suzetrigine. The multi-step synthesis route of suzetrigine is presented. Taking structural features into account, insights are provided into what plays a role for the inhibition of the NaV1.8 channel. In addition, pharmacodynamic and pharmacokinetic aspects of the new drug, such as bioavailability, metabolism, and interaction with CYP450 enzymes, are discussed. A summary based on a large number of clinical trials demonstrating remarkable efficacy completes this comprehensive drug profile of suzetrigine, while also addressing limitations of the clinical trials and suggesting future perspectives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium Channel BlockersNAV1.8 Voltage-Gated Sodium ChannelAnalgesicsPainHumansAnimalsAmidesAminopyridinesFurans

Stichwörter der Autor:innen

NaV1.8acute painnon-opioid analgesicsodium channelsuzetrigine

Substanzen

Sodium Channel BlockersNAV1.8 Voltage-Gated Sodium ChannelAnalgesicssuzetrigineAmidesAminopyridinesFurans

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria 21648, Egypt.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria 21648, Egypt.
  • Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195 Berlin, Germany.

ORCID-Profile: Rawan M Medhat, Omnia A Kotb, Daniel Baecker

Zitieren

APA

Medhat, R. M., Kotb, O. A., & Baecker, D. (2026). Suzetrigine, a NaV1.8 Inhibitor as a Novel Approach for Pain Therapy—A Medicinal and Chemical Drug Profile. Molecules, 31(2), 358. https://doi.org/10.3390/molecules31020358

Vancouver

Medhat RM, Kotb OA, Baecker D. Suzetrigine, a NaV1.8 Inhibitor as a Novel Approach for Pain Therapy—A Medicinal and Chemical Drug Profile. Molecules. 2026;31(2):358. doi:10.3390/molecules31020358

BibTeX
@article{Medhat2026,
  author = {Medhat, Rawan M and Kotb, Omnia A and Baecker, Daniel},
  title = {Suzetrigine, a NaV1.8 Inhibitor as a Novel Approach for Pain Therapy—A Medicinal and Chemical Drug Profile},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {2},
  pages = {358},
  doi = {10.3390/molecules31020358}
}
Kostenlos starten →